多巴胺D1类受体对血管平滑肌细胞胰岛素样生长因子1受体表达的影响

来源 :中华高血压杂志 | 被引量 : 0次 | 上传用户:xielinyun
下载到本地 , 更方便阅读
声明 : 本文档内容版权归属内容提供方 , 如果您对本文有版权争议 , 可与客服联系进行内容授权或下架
论文部分内容阅读
目的观察多巴胺 D_1类受体对血管平滑肌细胞胰岛素样生长因子1(IGF-1)受体的影响。方法以A10细胞为研究对象,免疫印迹观察刺激 D_1类受体对 IGF-1受体表达的影响,并初步探讨 D_1类受体对 IGF-1受体影响的机制。结果刺激 D_1类受体可降低 IGF-1受体的表达,D_1类受体阻断剂可完全阻断 D_1类受体激动剂Fenoldopam 对 IGF-1受体的影响,免疫印迹显示运用蛋白激酶 C(PKC)和促分裂原活化蛋白激酶(MAPK)阻断剂后,IGF-1受体表达恢复,提示 PKC 和 MAPK 途径可能参与了 D_1类受体对血管平滑肌细胞 IGF-1受体的影响过程,在 Wistar-Kyoto(WKY)大鼠和自发性高血压大鼠(SHR)血管平滑肌细胞中 D_1类受体激动剂 Fenoldopam 对IGF-1受体表达具有抑制作用,但该抑制作用在 SHR 细胞明显低于 WKY 细胞。结论 D_1类受体对血管平滑肌细胞 IGF-1受体表达具有抑制作用,该作用可能通过 PKC 和 MAPK 途径发挥一系列生理效应。 Objective To observe the effect of dopamine D_1 receptor on insulin-like growth factor 1 (IGF-1) receptor in vascular smooth muscle cells. Methods A10 cells were used as research objects. Immunoblotting was used to observe the effects of D_1 receptors on the expression of IGF-1 receptor and to explore the possible mechanism of D_1 receptors on IGF-1 receptor. Results The stimulation of D 1 receptors decreased the expression of IGF-1 receptor. The D 1 receptor blockers completely blocked the effect of D 1 -like receptor agonist Fenoldopam on IGF-1 receptor. Western blotting showed that protein kinase C (PKC) and mitogen activated protein kinase (MAPK) blockers, the expression of IGF-1 receptor was restored, suggesting that PKC and MAPK pathway may be involved in the process of IGF-1 receptor of vascular smooth muscle cells , D-type receptor agonist Fenoldopam had inhibitory effect on IGF-1 receptor expression in Wistar-Kyoto (WKY) rats and spontaneously hypertensive rats (SHR) vascular smooth muscle cells, but the inhibitory effect was obvious in SHR cells Lower than WKY cells. Conclusions D_1 receptors have an inhibitory effect on the expression of IGF-1 receptor in vascular smooth muscle cells. This effect may exert a series of physiological effects through PKC and MAPK pathways.
其他文献
清代叶天士在《临证指南医案·幼科要略》中记载:“小儿感冒,热病最多,以体属纯阳,六气着人,气血皆化为热也.”小儿肺脏娇嫩,卫外功能未固,对环境气候变化适应的能力及抗御外
尘肺是我国危害劳动者健康和生命安全最常见、最严重的职业病,近年发病人数约占我国职业病人数的80%,而目前在我国的工业企业中职业病危害最严重的生产岗位大多由农民工承担,
期刊
含砷类中药有悠久的应用历史,目前临床用于治疗恶性血液病的砷制剂包括雄黄制剂和砒霜提取液.雄黄制剂包括雄黄单味和含雄黄的复方,含雄黄的复方主要有青黄散、六神丸、复方青黛片等;砒霜提取液主要是As2O3注射液.研究表明,单—砷剂或含砷中药复方治疗恶性血液病,如急性早幼粒细胞白血病(APL)、慢性粒细胞性白血病(CML)、骨髓增生异常综合征(MDS)以及多发性骨髓瘤(MM)等均具有显著疗效[1].医学界